New drug combo could shrink head and neck tumors before surgery

NCT ID NCT06980038

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 30 times

Summary

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink tumors more than the immunotherapy alone in people with stage III-IV head and neck cancer. About 44 participants will receive either the combination or the single drug for a short time before their planned surgery. The goal is to see if the combo reduces the amount of tissue that needs to be removed and improves the body's immune response against the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emory University Hospital Midtown

    RECRUITING

    Atlanta, Georgia, 30308, United States

    Contact

    Contact Phone: •••-•••-••••

  • Ochsner Medical Center Jefferson

    RECRUITING

    New Orleans, Louisiana, 70121, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    RECRUITING

    Orange, California, 92868, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    RECRUITING

    Irvine, California, 92612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • VCU Massey Comprehensive Cancer Center

    RECRUITING

    Richmond, Virginia, 23298, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA LARYNGEAL SQUAMOUS CELL CARCINOMA NASAL CAVITY SQUAMOUS CELL CARCINOMA ORAL CAVITY SQUAMOUS CELL CARCINOMA OROPHARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA RECURRENT HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT NASAL CAVITY SQUAMOUS CELL CARCINOMA RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA STAGE III HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8 STAGE III LARYNGEAL CANCER AJCC V8 STAGE III LIP AND ORAL CAVITY CANCER AJCC V8 STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8 STAGE III NASOPHARYNGEAL CARCINOMA AJCC V8 STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 STAGE IV HEAD AND NECK CUTANEOUS SQUAMOUS CELL CARCINOMA AJCC V8 STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 STAGE IV OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 STAGE IVA LARYNGEAL CANCER AJCC V8 STAGE IVA LARYNGEAL CANCER AJCC V8 STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8 STAGE IVA LIP AND ORAL CAVITY CANCER AJCC V8 STAGE IVA NASOPHARYNGEAL CARCINOMA AJCC V8 STAGE IVA NASOPHARYNGEAL CARCINOMA AJCC V8 STAGE IVB LARYNGEAL CANCER AJCC V8 STAGE IVB LARYNGEAL CANCER AJCC V8 STAGE IVB LIP AND ORAL CAVITY CANCER AJCC V8 STAGE IVB LIP AND ORAL CAVITY CANCER AJCC V8